Pivotal Therapeutics raises $7.7 mln to advance heart disease treatment
Specialty pharmaceutical company Pivotal Therapeutics Inc (OTCQX: PVTTF) (CSE: PVO) has secured over $7.7 million in debt financing. The deal was led by U.S.-based Crossover Healthcare Fund, and included Broadfin Capital and Porter Capital Management. Combined with equity previously invested by Crossover, the company has to date raised over $10.4 million, which it will use for commercializing VASCAZEN®, a therapy focused on the Omega-3 deficiency needs of patients with cardiovascular disease, and other business purposes. Founded in 2010, Pivotal Therapeutics is based in Woodbridge, Ontario.
5 March 2014•4 mins read
